Atlas Venture Fund XI, L.P.'s Form 4 filing
Dyne Therapeutics, Inc. (DYN) · filed Feb 23, 2024
- Accession no.
- 0001415889-24-005124
- Filed
- Feb 23, 2024, 6:58 PM ET
- Trade date
- Feb 21-23, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions. Open-market sales total $11.3M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
| Atlas Venture Associates Opportunity I, L.P.CIK 0001780065 | 10% Owner |
| Atlas Venture Associates Opportunity I, LLCCIK 0001780066 | 10% Owner |
| Atlas Venture Associates XI, LLCCIK 0001780067 | 10% Owner |
| Atlas Venture Associates XI, L.P.CIK 0001780068 | 10% Owner |
| Atlas Venture Opportunity Fund II, L.P.CIK 0001885327 | 10% Owner |
| Atlas Venture Associates Opportunity II, LLCCIK 0001935810 | 10% Owner |
| Atlas Venture Associates Opportunity II, LPCIK 0001935814 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2024 | Common Stock | SSaleDisposed | −149,337 | $22.44F2 | −$3,351,122.28 | 6,666,628 | Direct | |
| Feb 21, 2024 | Common Stock | SSaleDisposed | −35,164 | $23.14F4 | −$813,694.96 | 6,631,464 | Direct | |
| Feb 22, 2024 | Common Stock | SSaleDisposed | −119,360 | $22.66F5 | −$2,704,697.6 | 6,512,104 | Direct | |
| Feb 23, 2024 | Common Stock | SSaleDisposed | −159,542 | $22.70F6 | −$3,621,603.4 | 6,352,562 | Direct | |
| Feb 23, 2024 | Common Stock | SSaleDisposed | −23,648 | $22.70F6 | −$536,809.6 | 1,585,137 | Indirect | |
| Feb 23, 2024 | Common Stock | SSaleDisposed | −13,738 | $22.70F6 | −$311,852.6 | 920,843 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.72 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6).
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7625 to $23.3899 inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $23.1566 inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.
Referenced by the price of 3 transactions in Table I.